Insider Selling: uniQure (NASDAQ:QURE) CEO Sells $7,287,493.28 in Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 164,429 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total transaction of $7,287,493.28. Following the sale, the chief executive officer owned 558,810 shares in the company, valued at approximately $24,766,459.20. The trade was a 22.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Performance

QURE opened at $48.85 on Thursday. The company has a 50 day simple moving average of $26.59 and a two-hundred day simple moving average of $22.65. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm has a market cap of $3.08 billion, a P/E ratio of -14.04 and a beta of 0.98. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. Equities analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

QURE has been the topic of several research analyst reports. Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Royal Bank Of Canada increased their target price on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. TD Cowen reissued a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Leerink Partners boosted their price target on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Finally, Chardan Capital upped their price target on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Twelve investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $58.92.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in shares of uniQure by 15.7% in the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after buying an additional 152,417 shares in the last quarter. Aberdeen Group plc grew its holdings in uniQure by 25.1% during the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after buying an additional 738,897 shares in the last quarter. Quinn Opportunity Partners LLC purchased a new position in uniQure during the 3rd quarter valued at approximately $6,281,000. Farallon Capital Management LLC increased its stake in uniQure by 3,935.7% in the 3rd quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock worth $32,979,000 after acquiring an additional 551,000 shares during the last quarter. Finally, Boone Capital Management LLC bought a new stake in uniQure in the 3rd quarter worth approximately $8,599,000. Institutional investors own 78.83% of the company’s stock.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure completed pricing on an upsized offering of 4,945,055 ordinary shares at $45.50 each, expected to raise about $225 million in gross proceeds. The added capital should strengthen the balance sheet and help fund its gene therapy pipeline. Article Title
• Neutral Sentiment: The company said the offering is expected to close around June 25, with underwriters also having a 30-day option to buy additional shares. This keeps financing flexibility high, but the near-term impact depends on completion and investor reception. Article Title
• Negative Sentiment: Investors appear worried about dilution because the company is issuing new shares rather than using debt. That pressure likely contributed to the stock’s weakness despite the capital raise. Article Title
• Negative Sentiment: Recent insider selling by the CEO and several directors may also weigh on sentiment, even though some trades were made under pre-arranged plans. Article Title

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.